A cohort mortality study among workers at a 1,3 butadiene facility

This is a cohort mortality study of 2800 male workers employed at least 6 m onths between 1943 and 1996 at a 1.3-butadiene monomer production facility. Earlier analyses of mortality for this cohort found statistically signific ant deficits for the 'all causes of death' category, and a lower than expec ted mortality for most leading causes of death. Past analyses also showed a significant elevation for deaths from cancers of the lymphohematopoietic s ystem that was mainly due to an increase in deaths from lymphosarcoma. The purpose of this update was to examine the patterns of mortality through the end of 1999, for five additional years of follow-up. Persons who had becom e eligible between the last cohort update and April 1996 were added. Cohort membership was closed after April 1996 due to the sale of the facility. A total of 1422 deaths through December 1999 were identified, giving over 200 more deaths than in the last report on this aging cohort. The standardized mortality ratio (SMR) for all causes of death was 89 [95% confidence inter val (95% CI) = 84-94], which is statistically significantly low, and that f or all malignant neoplasms was 90 (95% CI = 81 - 101). The SMR for all lymp hohematopoietic cancers (LHC) was 141 (95% CI = 105-186) and is statistical ly significant. The SMR for leukemia was 129 (95% CI = 77-204) and for non- Hodgkin's lymphoma (NHL), 148 (95% CI = 89-231). The LHC elevations again w ere found only in workers first employed before 1950 and, in the group with the highest potential for exposure to butadiene, the elevations were highe st in the short-term workers. Survival analyses were performed for all LHC [International Classification of Diseases (ICD) codes 200-209]. NHL (ICD co des 200, 202), and leukemia (ICD codes 204-207) using an estimate of cumula tive butadiene exposure as a time-dependent explanatory variable defined as a combination of job exposure class, calendar time, and length of time in job. The relative risks for the above causes of death were essentially 1.0, suggesting that there was no increase in risk with increasing butadiene ex posure. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.